Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Mar 3, 2025 · Learn about the drug trastuzumab (Herceptin), which is used to treat metastatic breast cancer and early breast cancer (including lymph node-positive and some lymph node-negative …

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive breast …

Dec 15, 2025 · A single line of prior endocrine therapy was permitted for advanced or metastatic breast cancer.

Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

3 days ago · Herceptin (chemical name: trastuzumab) is a HER2 inhibitor targeted therapy. Herceptin works against HER2-positive breast cancers by blocking the ability of the cancer cells to receive …

Dec 15, 2025 · The FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu; Daiichi Sankyo, Inc., AstraZeneca) in combination with pertuzumab (Perjeta; Genentech) for the first-line treatment of …

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.

Apr 14, 2024 · Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Dec 15, 2025 · The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or …